PDGFRA and soft tissue sarcoma: Moreover, recent data on olaratumab, a recombinant human IgG1 monoclonal antibody that specifically binds PDGFRA and receptor activation, and its FDA approval, may significantly improve outcome of patients with soft tissue sarcoma.